Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
NewcelX ( (NCEL) ) has shared an announcement.
On November 17, 2025, NewcelX Ltd. announced the appointment of Prof. Jeremy Shefner, MD, PhD, to its Scientific Advisory Board. Prof. Shefner, a respected neurologist specializing in ALS and neuromuscular disorders, will provide strategic guidance on NewcelX’s ALS programs, including the clinical development of AstroRx®. His appointment is expected to enhance the company’s ability to advance therapies for neurodegenerative diseases, reinforcing its commitment to scientific excellence and clinical execution.
More about NewcelX
NewcelX Ltd. is a biotechnology company focused on developing cell-based and small-molecule therapies for neurodegenerative and metabolic diseases. The company combines advanced stem-cell technologies with neuroscience expertise to create treatments for conditions such as ALS and Type 1 Diabetes. Headquartered in Zurich, Switzerland, NewcelX conducts its research and development operations in Israel.
Average Trading Volume: 182,618
Technical Sentiment Signal: Sell
Current Market Cap: $1.48M
For detailed information about NCEL stock, go to TipRanks’ Stock Analysis page.